Classifica tra le azioni
#28265
Syntara Limited is a clinical-stage biopharmaceutical company dedicated to... Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders. Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates. These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation. The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.
Prezzo delle azioni
$0.0183374
Capitalizzazione di mercato
$27.51M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
9.62%
Scambia Syntara Limited (SNT)
Utile per Syntara Limited (SNT)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Syntara Limited, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Syntara Limited dal 2026 al 2026
Utile alla fine di ogni anno
| Anno |
Utile |
Cambia |
|
Non abbastanza dati per le date fornite. |
Utile per aziende simili o concorrenti
| Azienda |
Utile |
Differenza negli utili |
Il paese |
|
|
- |
-
|
DE
|
|
|
- |
-
|
DE
|
|
|
- |
-
|
JP
|
|
|
- |
-
|
CH
|
|
|
$1.76B |
-
|
IN
|
